Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

PUBLICATIONS

Therapeutic efficacy of FASN inhibition in preclinical models of HCC

By Graviton / 01/2022

Hepatology

TVB-2640, a novel, first-in-class, fatty acid synthase (FASN) inhibitor: biomarker and metabolomic correlations with clinical MRI-PDFF response

By Graviton / 11/2021

NASH Summit

Novel, first-in-class, fatty acid synthase (FASN) inhibitor TVB-2640 demonstrates robust clinical efficacy and safety in a global phase 2 randomized placebo-controlled NASH trial (FASCINATE-1) conducted in the U.S. and China

By Graviton / 11/2021

AASLD The Liver Meeting

Translation of FASN Inhibitor TVB-2640 from Preclinical MOA to Clinical POC in NASH

By Graviton / 09/2021

NASH and Fibrosis Conference

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

By Graviton / 07/2021

Gastroenterology

Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640

By Graviton / 06/2021

EASL International Liver Congress

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

By Graviton / 04/2021

EClinicalMedicine

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

By Graviton / 11/2020

AASLD

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

By Graviton / 09/2020

European Society for Medical Oncology (ESMO) Congress

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

By Graviton / 08/2020

EASL International Liver Congress

Post pagination

← Previous 1 … 4 5 6 … 10 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top